IMMUCELL CORP /DE/ (ICCC) Form 10-Q — Aug 13, 2026
ImmuCell's 10-Q for the quarter ended June 30, 2026 shows Q2 product sales of $7.2 million, up 11.5% year over year, and first-half sales of $17.5 million, up 20.9%, driven by higher First Defense volumes, portfolio expansion and price increases effective January 1, 2026. Q2 net income jumped 265.6% to $1.8 million ($0.20 diluted EPS) and H1 net income reached $3.8 million ($0.41 diluted), but the quarter included a one-time $2.0 million settlement from former contract manufacturer Norbrook Laboratories related to Re-Tain development costs — excluding it, Q2 would have been roughly break-even.
Key figures
- Eps
- 0.2
- Revenue
- 7186113
- Net Income
- 1834656
- Total Debt
- 8302886
- Cash Position
- 8860205
- Shares Outstanding
- 9082197
- H1 revenue
- 17543408
- H1 eps basic
- 0.42
- Total assets
- 46629796
- H1 net income
- 3776263
- H1 eps diluted
- 0.41
- Q2 gross profit
- 2437222
- Q2 eps prior year
- 0.06
- H1 revenue yoy pct
- 20.9
- Line of credit usd
- 1000000
- Q2 revenue yoy pct
- 11.5
- Stockholders equity
- 31374536
- Atm program size usd
- 11000000
- Line of credit expiry
- September 11, 2026
- Q2 net income yoy pct
- 265.6
- H1 operating cash flow
- 6592102
- Q2 gross profit yoy pct
- -13.5
- One time settlement gain
- 2000000
- Expansion phase1 cost usd
- 3500000
- Expansion phase2 cost usd
- 4500000
- Atm capacity remaining usd
- 6000000
- H1 2025 operating cash flow
- 3175334
- Expected 2026 interest expense
- 367000
- Weighted avg interest rate pct
- 4.29
- International sales pct q2 2026
- 13.4
- Expected 2026 debt principal repayments
- 1600000
Price after filing
Close on the filing date to close N calendar days later (from $10.95). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.